Home » Health Policy » Pharmaceutical Policy and Regulation

Category Archives: Pharmaceutical Policy and Regulation

Sky-High Drug Prices for Rare Diseases Show Why Orphan Drug Act Needs Reform

The Orphan Drug Act (ODA) was passed 34 years ago to promote development of drugs aimed at diseases that afflict small groups, typically under 200,000 people. However, the nature of drug development has changed. Our researchers see an opportunity for improvement. (more…)

Election verdict: Pharma Needs a New Prescription

Dana Goldman and Darius Lakdawalla provide a policy prescription list for the pharmaceutical industry aimed at improving access for patients today without discouraging investments into tomorrow’s medical innovations.  (more…)

Encouraging Integrative, Non-Opioid Approaches To Pain: A Policy Agenda

National initiatives are underway to dramatically reduce access to prescription opioids, but these efforts lack a systematic approach to provide alternative treatments for these patients. Jason Doctor and his colleagues outline three feasible policy initiatives.  (more…)

To Prevent Another EpiPen Controversy, the Government Should Step In

The real problem is with lax regulatory oversight that doesn’t ensure an adequate supply of drugs critical to population health and opens the door to shocking price increases.  (more…)

Can Shopping Around for Prescriptions Save Money?

Research conducted by USC Price MPP students found huge variation in prescription drug prices when shopping around at pharmacies in the LA area.  Based on their experience, they recommend four strategies consumers should use to get the lowest price. (more…)

Finding an Answer to the Hepatitis C Cost Conundrum

We need to shift our treatment strategy to one that treats patients at the optimal time, thereby maximizing the treatment’s effectiveness and controlling costs for payers. (more…)

What the candidates don’t get about drug prices

If you are like me, you are watching with relish the presidential debates on both the Republican and Democratic side. Sometimes, amid the reality show-type theatrics, they actually substantive discussions about issues like Social Security, (more…)

A Medication Lock-In Program May Not Be the Easy Solution to the Opioid Abuse Epidemic That Congress Thinks It Is

According to the CDC, in 2010 enough opioid pain relievers were sold to (more…)

For Vulnerable Populations, the Medicare Part D Doughnut Hole Disrupts Medication Adherence

During the annual Medicare Open Enrollment period, senior citizens (more…)

A New Line of Specialty Drugs: PCSK9 Inhibitors (Part 2)

This fall, a new line of specialty drugs will hit the market- PCSK9 inhibitors.  PCSK9 inhibitors are a new class of drugs used to lower LDL (bad) cholesterol levels through stifling a protein (PCSK9). The drug is injected once or twice a month and is (more…)

Follow CESR on Facebook



Follow Schaeffer on Facebook




Subscribe to receive updates